Aims & Scope:

Epigenetics is defined as heritable changes in gene expression that do not result from an alteration in the DNA sequence itself. DNA/RNA modification, histone variants and modifications, and nucleosome positioning work together to determine the epigenetic landscape of a cell. Until now, there is a growing awareness that epigenetic dysregulation plays a significant role in many types of diseases, and that is fueling an increasing number of studies into drugs that target epigenetic regulators, and several epigenetic targeted drugs have entered into clinical trials, or in the market, including DNA methyltransferase inhibitor, bromo domain reader inhibitor, histone acetylase or deacetylase inhibitor, histone methyltransferase or demethylase inhibitor, deubiquitinase inhibitor or neddylation inhibitor. Due to the fast-growing number of epigenetics and epigenetic targeted drugs, it is becoming a hot area in drug discovery for cancer therapy. In this thematic issue, reviews about epigenetic modification related drug target, drug discovery, assay development, biological function, molecular modeling, target structure analysis are welcome.

Schedule:

- Manuscript submission deadline: October 2019

Contacts:

Guest Editor: Dr. Yi-Chao Zheng,
Affiliation: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, P.R. China
Email: yichaozheng@zzu.edu.cn; demethylase@163.com

Any queries should be addressed to cdt@benthamscience.net